BioMedNewsBreaks

ThursdayOct 23, 2025 12:57 pm

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) CEO Discusses IzoView Commercialization Strategy in New Departures Capital Interview 

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing advanced imaging technologies for the detection and treatment of breast cancer, announced the release of a new video interview with CEO Bob Thast in partnership with Departures Capital. The discussion highlights Izotropic’s vision and near-term strategy for its flagship IzoView breast CT platform, detailing its imaging advantages, patient benefits, and market differentiation. Thast also outlines plans for capital deployment over the next 12–18 months, including production of three IzoView units for an upcoming U.S. FDA clinical study, a partner device in the U.K. to support CE-mark activities, and…

Continue Reading

ThursdayOct 23, 2025 11:35 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics (OTCQB: OTLC), a biopharmaceutical company developing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that three abstracts featuring its investigational intravenous Deciparticle (TM) everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9–12 in San Antonio, Texas. Developed by Sapu Nano—a joint venture between Oncotelic and Dragon Oversea—Sapu003 is a novel IV formulation of everolimus designed to overcome the limitations of oral mTOR inhibitors such as Afinitor (R), including poor bioavailability and restricted tumor penetration. The abstracts collectively detail the clinical rationale, molecular biomarkers,…

Continue Reading

WednesdayOct 22, 2025 2:03 pm

BioMedNewsBreaks — Branded Legacy, Inc. (OTC: BLEG) Advances FDA Pathway for Intranasal Naloxone with Pre-ANDA Briefing Preparation

Branded Legacy (OTC: BLEG), a holding company focused on life sciences and wellness innovation, announced that its subsidiary, BioLegacy Evaluative Group, has begun preparing its FDA Pre-Abbreviated New Drug Application (Pre-ANDA) briefing package for a proprietary intranasal naloxone spray. The milestone follows BioLegacy’s provisional patent filing for its air-driven delivery platform, designed to offer a cost-effective, scalable solution to the opioid overdose crisis. The submission includes a Target Product Profile for 2 mg and 4 mg naloxone HCl nasal sprays, Chemistry, Manufacturing and Controls specifications, a 60-subject bioequivalence study against Narcan(R), and human factors testing to ensure accessibility for non-medical users.…

Continue Reading

WednesdayOct 22, 2025 11:14 am

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in NetworkNewsWire Editorial on AI-Driven 3D Imaging for Breast Cancer Detection

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), developer of the IzoView Breast CT Imaging System, announces its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Investors Eye Next-Gen 3D AI-Imaging Technologies in Growing $9 Billion Market.” The piece highlights how artificial intelligence is transforming medical imaging, particularly in breast cancer diagnostics, where early and accurate detection remains critical. Izotropic’s dedicated 3D imaging platform is designed to enhance detection precision, especially for women with dense breast tissue, positioning the company at the forefront of innovation in a rapidly expanding global market. To view the full press release, visit https://ibn.fm/saP3D About Izotropic Corporation Izotropic…

Continue Reading

WednesdayOct 22, 2025 9:15 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results 

Soligenix (NASDAQ: SNGX) is continuing to build momentum in the treatment of early-stage cutaneous T-cell lymphoma (“CTCL”) through promising results from its pivotal FLASH trial and ongoing FLASH 2 confirmatory study. HyBryte(TM)—a novel, non-UV light-activated therapy using synthetic hypericin—has demonstrated statistically significant efficacy and safety, offering hope in a field where therapeutic innovation has lagged. In the original FLASH study, nearly half of patients showed meaningful response at 18 weeks, and interim results from an independent University of Pennsylvania study reported a 75% response rate. FLASH 2 builds on these findings with improved design while addressing regulatory requirements for confirmatory…

Continue Reading

FridayOct 17, 2025 2:54 pm

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Unveils IzoView: A Game-Changing Platform for Next-Gen Breast Cancer Detection

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) is leading a transformation in breast cancer screening with its flagship IzoView Breast CT Imaging System, a next-generation technology designed to overcome the long-standing limitations of traditional mammography. Unlike compression-based 2D imaging, IzoView delivers true 360-degree, 3D visualization without discomfort, enabling clearer detection—especially in dense breast tissue, which often obscures lesions in standard scans. With a rapid 10-second scan time, high spatial resolution surpassing MRI, and radiation levels comparable to conventional mammography, the system streamlines diagnosis while enhancing patient safety and experience. Built as a scalable platform, IzoView supports future software-driven clinical applications—from screening…

Continue Reading

FridayOct 17, 2025 2:21 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed its efforts to pioneer RNA candidates and strategic programs aimed at some of the most lethal and overlooked cancers. “Immunotherapy and RNA-based approaches have begun to reshape the understanding of cancer treatment. The FDA approved 17 new immunotherapies in 2024 alone, spanning multiple cancer types and delivering breakthroughs such as checkpoint inhibitors and individualized vaccines. Yet despite this progress, significant unmet needs persist, particularly in rare pediatric cancers, resistant solid tumors and underserved population. Oncotelic is strategically positioned to fill gaps where traditional treatments fall short,” the article reads.…

Continue Reading

ThursdayOct 16, 2025 2:38 pm

BioMedNewsBreaks — NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advances KETAFREE(TM), Expands Pipeline Targeting Urgent Needs

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, recently secured approval from the U.S. Food and Drug Administration (“FDA”) for its Suitability Petition to advance KETAFREE(TM), a preservative-free version of ketamine. “The ruling allows the company to re-file its Abbreviated New Drug Application (‘ANDA’) for the product, which it has now done, a key step in bringing it to market,” reads a recent article. “Currently, ketamine is sold in multidose vials that require preservatives to maintain sterility after repeated use. The most common additive, Benzethonium Chloride, is known to be toxic. NRx’s proposed alternative eliminates preservatives by using single-patient dosing,…

Continue Reading

ThursdayOct 16, 2025 1:55 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Combining Portability and Precision to Redefine Future of Cardiac Care

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its development of a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. “The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems… The VALID-ECG study results carry significant weight for both clinical adoption and HeartBeam’s commercialization pathway,” reads the article. “For HeartBeam, the upcoming commercialization of its ECG system represents more than a regulatory milestone; it is a potential step toward redefining how heart…

Continue Reading

WednesdayOct 15, 2025 11:33 am

BioMedNewsBreaks — Adageis CEO Discusses AI-Driven Solutions for Value-Based Care in Latest Bell2Bell Podcast 

Adageis, a healthcare technology company revolutionizing patient care through innovative digital solutions, is featured in the latest episode of The Bell2Bell Podcast, produced by IBN, a multifaceted communications organization connecting public companies with the investment community. In the interview, Adageis CEO Shane Speirs explains how the company’s AI-powered platform simplifies the administrative challenges of delivering value-based care by digitizing complex insurance and compliance processes. “We make it easy to see what measures practices need to hit and how to hit them for each individual patient,” Speirs said, noting that Adageis currently supports more than 580,000 patient lives. The conversation explores…

Continue Reading